"Each attack can result in potentially irreversible consequences -- causing blindness or losing the ability to walk -- so preventing relapse is the primary goal," said Michael Levy at Massachusetts General Hospital. "There is now for the first time an FDA-approved treatment available to NMOSD patients to help reduce the risk of relapse."
Price: 126.06, Change: +0.72, Percent Change: +0.57
|Analyst Actions: CLSA Downgrades New Oriental Educat...|
|Market Chatter: VirnetX Holding Loses Appeal Over In...|
|--Analyst Actions: SunTrust Downgrades MGP Ingredien...|
|Analyst Actions: Morgan Stanley Lifts Price Target o...|
|Analyst Actions: Cross Research Downgrades Littelfus...|